Logo

ALLO

Allogene Therapeutics, Inc.

ALLO

Allogene Therapeutics, Inc. • NASDAQ
$1.46 ▲ 2.82% (+0.04)
Market Cap $328.11 M
52w High $3.78
52w Low $0.86
Dividend Yield 0%
P/E -1.49
Volume 976.19K
Outstanding Shares 224.73M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $13.737M ▼ $-41.4M ▲ 0% $-0.19 ▲ $-37.959M ▲
Q2-2025 $0 $56.819M ▼ $-50.943M ▲ 0% $-0.23 ▲ $-47.569M ▲
Q1-2025 $0 $62.092M ▲ $-59.733M ▲ 0% $-0.28 $-56.484M ▼
Q4-2024 $0 $57.257M ▼ $-59.939M ▲ 0% $-0.28 ▲ $-56.182M ▲
Q3-2024 $0 $71.774M $-66.293M 0% $-0.32 $-62.986M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $252.194M ▼ $439.771M ▼ $124.442M ▼ $315.329M ▼
Q2-2025 $273.12M ▼ $470.593M ▼ $126.032M ▲ $344.561M ▼
Q1-2025 $280.043M ▼ $507.982M ▼ $122.589M ▼ $385.393M ▼
Q4-2024 $292.476M ▲ $548.71M ▼ $126.531M ▲ $422.179M ▼
Q3-2024 $291.564M $589.12M $125.372M $463.748M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-41.4M ▲ $-29.688M ▲ $11.935M ▼ $3.236M ▼ $-14.517M ▼ $-29.931M ▲
Q2-2025 $-50.943M ▲ $-39.03M ▲ $43.835M ▲ $5.072M ▼ $9.877M ▲ $-39.074M ▲
Q1-2025 $-59.733M ▲ $-52.929M ▼ $6.176M ▼ $13.99M ▲ $-32.763M ▼ $-53.028M ▼
Q4-2024 $-59.939M ▲ $-36.698M ▲ $54.934M ▲ $5.743M ▲ $23.979M ▲ $-36.955M ▲
Q3-2024 $-66.293M $-44.115M $-75.992M $679K $-119.428M $-44.544M

Revenue by Products

Product Q1-2025Q2-2025Q3-2025
License
License
 $0 ▲$0 ▲$0 ▲

Five-Year Company Overview

Income Statement

Income Statement Allogene is still very much a development‑stage biotech company, so it has essentially no product revenue. Its income statement is driven by research and development and overhead costs, which lead to consistent annual losses. Those losses have been sizable but are not unusual for a company funding multiple advanced clinical programs. Over the last couple of years, the loss per share has started to improve a bit, suggesting some discipline in spending or efficiency gains, but the business remains far from break‑even and depends on external funding rather than self‑generated cash.

Balance Sheet

Balance Sheet The balance sheet shows a company gradually drawing down its resources to fund R&D. Total assets and shareholders’ equity have steadily declined from earlier years, reflecting ongoing losses and cash usage. The cash balance has moved down over time and is now meaningfully lower than at the start of the period, though still meaningful enough to support operations for a time. Debt exists but remains modest relative to equity, so the capital structure is still equity‑heavy and not highly leveraged. Overall, the balance sheet is adequate for a clinical‑stage biotech but clearly on a use‑of‑cash trajectory, which will likely require future capital raises unless results change.

Cash Flow

Cash Flow Cash flow patterns are typical of a high‑R&D biotech without products on the market. Operating cash flow is consistently negative, driven by spending on clinical trials, manufacturing capabilities, and general operations. Free cash flow is also clearly negative, closely tracking operating cash outflows, since capital spending has been present but not very large and has trended down from the early build‑out years. In simple terms, the business burns cash every year, and there is no offsetting inflow from commercial sales yet. This makes timing and size of future financing an important ongoing consideration.

Competitive Edge

Competitive Edge Allogene operates in a very competitive and rapidly evolving corner of biotechnology: cell therapies for cancer and autoimmune disease. Its focus on “off‑the‑shelf” allogeneic CAR‑T is a meaningful differentiator versus traditional, patient‑specific CAR‑T approaches. This model aims to offer faster treatment, more scalable manufacturing, and potentially lower costs. The company has built a recognizable brand in this niche, with a growing clinical dataset and proprietary technologies like its Dagger platform and Alloy manufacturing process. At the same time, it faces competition from both other allogeneic players and established autologous CAR‑T companies. The field is crowded, scientific risk is high, and timing of clinical successes or setbacks can quickly change relative positioning.

Innovation and R&D

Innovation and R&D Innovation is the core of Allogene’s value proposition. The company is advancing a portfolio of allogeneic CAR‑T candidates across blood cancers, solid tumors, and now autoimmune diseases. Its lead program in lymphoma is being tested in earlier‑line settings as a consolidation therapy, which, if successful, could shift how certain patients are treated. Another program targets kidney cancer, testing whether off‑the‑shelf CAR‑T can work meaningfully in solid tumors, an area where the field has historically struggled. A newer candidate for autoimmune diseases combines dual targeting with its Dagger technology to potentially reduce or avoid harsh preconditioning. Underpinning this is a platform of gene‑editing and manufacturing capabilities aimed at making cell therapy more scalable and practical. The upside is substantial if these approaches translate into strong clinical results, but the programs are still in development, so clinical, regulatory, and execution risks remain high.

Summary

Allogene is a classic clinical‑stage biotech story: a company with ambitious technology and a diversified pipeline, but no commercial products yet. Financially, it runs sizable annual losses and steady cash burn, funded by a balance sheet that remains reasonable but has been gradually depleted over the last several years. Strategically, its bet on off‑the‑shelf CAR‑T therapies, supported by proprietary editing and manufacturing tools, gives it a clear identity and potential edge in accessibility and scalability compared with traditional CAR‑T approaches. The near‑ to medium‑term outlook hinges heavily on pivotal and early‑stage clinical readouts in lymphoma, kidney cancer, and autoimmune diseases. Success could validate its model and expand its opportunity; setbacks could intensify financing pressure and competitive challenges. Overall, this is a high‑innovation, high‑uncertainty profile typical of advanced, pre‑commercial biotech companies.

NEWS

November 10, 2025 · 8:30 AM UTC

Allogene Therapeutics Announces Participation in Upcoming Investor Conferences

Read more

November 6, 2025 · 4:05 PM UTC

Allogene Therapeutics Reports Third Quarter 2025 Financial Results and Business Update

Read more

November 3, 2025 · 9:04 AM UTC

Allogene Therapeutics Announces ALPHA3 Trial-in-Progress Poster Presentation at ASH Annual Meeting

Read more

October 30, 2025 · 8:30 AM UTC

Allogene Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update

Read more

October 17, 2025 · 5:00 PM UTC

ALLO Enables Equal Access To Secure Wi-Fi for All Students With Calix SmartTown for Education

Read more